Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01569204 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)

Study Title
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma (NCT01569204)

Trial Description
The purpose of this clinical trial is to determine the complete response rate (CRR) after six cycles of chemotherapy, as well as to determine the complete remission rate (CR/CRr) as final treatment outcome after completion of treatment. In this trial, the BEACOPP Variant is a chemotherapy regimen consisting of etoposide, cyclophosphamide, doxorubicin hydrochloride, prednisone, procarbazine, dexamethasone, dacarbazine and brentuximab vedotin, used for the treatment of advanced-stage Hodgkin lymphoma (HL).

This trial is sponsored by University of Cologne. [1]

Study Data

  • Condition: Hodgkin Lymphoma
  • Interventions:
  • Phase: II
  • Estimated Enrollment: 100
  • Start: October 2012
  • Estimated Completion: December 2015
  • Last verified: December 2014

Click here for an overview of other trials with brentuximab vedotion.

Study Schematic

(CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)

Click here to Return to Drug map


Last Editorial review: July 20, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

* While generic versions of this drug are still available, this Brand Name drug is no longer available in the United States.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar